Navigation Links
Diabetes Insight Could Lead to Better Treatments
Date:12/21/2009

Inhibiting a key inflammatory pathway brought powerful results in mice and people, researchers say

MONDAY, Dec. 21 (HealthDay News) -- Scientists have identified a protein that may be involved in the development of type 2 diabetes, a finding that could lead to new drugs to fight this growing worldwide scourge.

This same group of researchers recently showed that inhibiting this pathway worked to block pain associated with gout, an inflammatory condition affecting the joints.

Inflammation also plays a large role in diabetes.

The authors of this study, published online Dec. 21 in Nature Immunology, started their exploration with the NLRP3 inflammasome, which has been linked with different inflammatory diseases.

Inflammasomes are clusters of proteins that stimulate inflammation and play a role in the body's innate immune response, explained Dr. Norma Kenyon, professor at the Diabetes Research Institute of the University of Miami Miller School of Medicine. She is familiar with the new findings.

"The inflammasome sense situations that are dangerous to our body," added study senior author Jurg Tschopp, a professor at the University of Lausanne in Epalinges, Switzerland. "This includes pathogens (bacteria, viruses), but also endogenous 'danger situations,' such as uric acid crystals found in gout, high circulating glucose found in diabetes or beta-amyloid [plaques] found in Alzheimer's disease."

Until now, scientists were unable to figure how out the NLRP3 inflammasome is activated. With that information now in hand, researchers might have another promising route to developing treatments for type 2 diabetes.

The chain of events seems to start with a protein called TXNIP, which, when exposed to oxidative stress, binds to NLRP3 and leads to the production of interleukin-1 beta or IL-1b, an immune system molecule.

IL-1b is also produced by the pancreas' islet cells as a response to high blood sugar. These islet cells are also responsible for secretion of insulin.

To determine if islet production of IL-1b was caused by the interaction of NLRP3 and TXNIP, the researchers exposed islet cells from normal mice and from mice deficient in NLRP3 or TXNIP to high glucose levels. As predicted, the protein-deficient islets made less IL-1b.

What's more, these deficient mice cleared glucose from the bloodstream quicker in response to insulin.

"Our findings predict that type 2 diabetes can be treated by inhibitors of the inflammasome or IL-1b," Tschopp said.

The good news is that these effects of NLRP3 are confined to the insulin-producing beta cells of the pancreas, so compounds to inhibit the pathway should not have systemic effects.

Studies in humans are already under way. According to Tschopp, "clinical studies with type 2 diabetes patients have already been initiated and the first results are again incredibly encouraging. With a single injection of IL-1b inhibitors, glucose levels in diabetes patients are highly reduced during six months. This treatment could replace the standard treatment currently used."'

More information

There's more on type 1 and type 2 diabetes at the American Diabetes Association.



SOURCES: Jurg Tschopp, Ph.D., professor, University of Lausanne, Epalinges, Switzerland; Norma Kenyon, M.D., Martin Kleiman professor of surgery, medicine, microbiology and immunology and biomedical engineering, Diabetes Research Institute, University of Miami Miller School of Medicine; Dec. 21, 2009, online Nature Immunology


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Orameds Dr Roy Eldor was Chosen to Lecture at the First International Conference Held by the Bildirici Center for Diabetes Care Research in Israel.
2. UCSF/SFGH project for diabetes patients wins award for innovation, quality
3. SFGH Project for Diabetes Patients Wins Award for Innovation, Quality
4. Sermo Vitals Report(TM) Quantifies One Year of Physician Conversation About Diabetes
5. TrekDesk: A Potentially Positive Impact on Diabetes & Obesity
6. Coffee, Tea Might Stave Off Diabetes
7. UNC scientists coordinate study of link between insulin use and cancer in people with diabetes
8. Study finds over 90 percent of people with gum disease are at risk for diabetes
9. Study shows how gene action may lead to diabetes prevention, cure
10. Bears Quarterback Jay Cutler and Eli Lilly and Company Will Send 44 Kids to American Diabetes Association Camps Through the Touchdowns for Diabetes Campaign
11. Chinese-American and Korean-American women at highest risk for diabetes in pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... Lori R. Somekh, founder of the Law Office of Somekh ... law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up ... network with elder law attorneys nationwide,” said Somekh. , ElderCounsel was ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association ... Featuring a collection of specialty vendors and unique items from across the nation, this ... health and wellness services offered by the VNA. The boutique will be open ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/19/2017)... ZirMed Inc ., a recognized leader in cloud-based revenue cycle ... ranked #1 by its users for the seventh consecutive year ... ZirMed was recognized as the top-ranked end-to-end revenue cycle management ... 200 beds and holds one of the longest #1 ranking ... ...
Breaking Medicine Technology: